Regulatory Inspection
FDC Discloses FDA Maharashtra Action Involving Stock Seizure and Sample Collection of Enerzal Product
NSE
fdc
BSE
531599
FDC Limited informed stock exchanges that officials from the Food & Drug Administration (FDA), Maharashtra, visited the company’s depot/warehouse in Nagpur and seized certain stock of its product Enerzal while collecting samples for examination. The company stated that the final examination order is yet to be received and that business operations continue normally with no material financial impact reported.
PRICE-SENSITIVE TRIGGER
Event: Food & Drug Administration, Maharashtra conducted inspection, seized stock, and collected product samples for examination.
Type: Regulatory Inspection
Impact: Negative
Immediate Effect: The regulatory action creates compliance-related uncertainty around the affected product until examination results and the final order are received from the authority.
What Happened ?
FDC Limited disclosed that Food Safety Officials from the Food & Drug Administration, Maharashtra, visited the company’s depot and warehouse located at Chhatrapati Sambhaji Nagar and Nagpur.
During the visit, the authority seized certain stock of the company’s product Enerzal and collected samples for examination. According to the company, the action was undertaken as part of a regulatory process and the final examination order has not yet been received.
The company stated that it intends to pursue appropriate legal recourse and that business operations continue as normal.
Key Details
FDA Maharashtra Inspection and Product Examination:
- Regulatory authority involved is Food & Drug Administration, Maharashtra.
- Action relates to the company’s product Enerzal.
- Officials visited the company’s depot/warehouse facilities.
- Certain stock was seized by the authority.
- Product samples were collected for examination.
- Communication was received on 3 June 2026.
- Examination relates to alleged misbranding of the product.
- Final examination order is yet to be received.
- Company intends to take appropriate legal recourse.
- Business operations continue normally.
- No material operational disruption has been reported.
- Disclosure made under Regulation 30 of SEBI (LODR) Regulations.
Note:
- At this stage, the matter remains under examination by the regulatory authority. The outcome will depend on laboratory findings, regulatory assessment, and any subsequent order issued by FDA Maharashtra.
Risk Analysis
Summary:
- The key risk relates to the outcome of the product examination and potential regulatory findings regarding alleged misbranding.
Key Risks:
- Final examination report is still pending.
- Regulatory authorities may issue further directions based on findings.
- Adverse conclusions could result in product-related restrictions or corrective actions.
- Reputational impact may arise if allegations are substantiated.
- Additional compliance requirements may emerge following the review.
- Future legal proceedings cannot be ruled out.
Worst Case Scenario:
- If the examination confirms regulatory violations or product misbranding, the company could face product recalls, penalties, restrictions, corrective labeling requirements, or reputational damage.
Risk Level: Medium
Company Commentary
- FDA Maharashtra officials visited the company’s warehouse/depot facilities.
- Certain stock of Enerzal was seized and samples were collected for examination.
- Final examination order has not yet been received.
- The company will pursue appropriate legal recourse.
- There is no material financial impact on the company as of date.
- There is no material impact on operations as of date.
- Business operations continue as usual.
- Any further material development will be disclosed upon conclusion of the matter.
Official Exchange Filing: FDC Limited